Efficacy and Safety of Pioglitazone in a Phase 1/2 Imatinib Discontinuation Trial ( EDI‐PIO ) in Chronic Myeloid Leukemia with Deep Molecular Response
Journal article published in 2020 by
Katia B. B. Pagnano 
,
Ana Beatriz P. Lopes,
Eliana C. Miranda,
Márcia T. Delamain,
Gislaine O. Duarte,
Bruna R. V. Rodrigues,
Valquiria M. O. Povoa,
Graziele C. P. Furlin,
Jessica C. Vianna,
Matheus A. S. Silva,
Carmino A. De Souza ,
Erich V. De Paula
,
Ana Beatriz P. Lopes,
Eliana C. Miranda,
Márcia T. Delamain,
Gislaine O. Duarte,
Bruna R. V. Rodrigues,
Valquiria M. O. Povoa,
Graziele C. P. Furlin,
Jessica C. Vianna,
Matheus A. S. Silva,
Carmino A. De Souza ,
Erich V. De Paula
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 